Patients with high expression of RUNX3 showed better tumor regression response and down-staging compared with those with low expression of RUNX3.46 There is currently few research on EZH2 expression alterations before and after rectal cancer neoadjuvant therapy. The gene discussed is RUNX3; the disease is neoplasm.